NASDAQ:OCUP - Ocuphire Pharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $21.75
  • Forecasted Upside: 343.88 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$4.90
▼ -0.08 (-1.61%)

This chart shows the closing price for OCUP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ocuphire Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OCUP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OCUP

Analyst Price Target is $21.75
▲ +343.88% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Ocuphire Pharma in the last 3 months. The average price target is $21.75, with a high forecast of $25.00 and a low forecast of $20.00. The average price target represents a 343.88% upside from the last price of $4.90.

This chart shows the closing price for OCUP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Ocuphire Pharma.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/5/2021Alliance Global PartnersInitiated CoverageBuy$25.00High
3/29/2021JonestradingInitiated CoverageBuy$20.00High
3/15/2021Cantor FitzgeraldBoost Price TargetOverweight ➝ Positive$15.00 ➝ $20.00High
2/10/2021Canaccord GenuityInitiated CoverageBuy$22.00Low
11/19/2020Cantor FitzgeraldInitiated CoverageOverweight$15.00High
(Data available from 6/21/2016 forward)
Ocuphire Pharma logo
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of various eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances, and pharmacologically induced mydriasis, as well as that is in Phase II clinical trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.
Read More

Today's Range

Now: $4.90
Low: $4.87
High: $5.03

50 Day Range

MA: $4.82
Low: $4.24
High: $5.74

52 Week Range

Now: $4.90
Low: $3.68
High: $13.81

Volume

11,595 shs

Average Volume

364,878 shs

Market Capitalization

$61.56 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.46

Frequently Asked Questions

What sell-side analysts currently cover shares of Ocuphire Pharma?

The following equities research analysts have issued reports on Ocuphire Pharma in the last twelve months: Alliance Global Partners, Canaccord Genuity, Cantor Fitzgerald, Jonestrading, and Zacks Investment Research.
View the latest analyst ratings for OCUP.

What is the current price target for Ocuphire Pharma?

4 Wall Street analysts have set twelve-month price targets for Ocuphire Pharma in the last year. Their average twelve-month price target is $21.75, suggesting a possible upside of 343.9%. Alliance Global Partners has the highest price target set, predicting OCUP will reach $25.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $20.00 for Ocuphire Pharma in the next year.
View the latest price targets for OCUP.

What is the current consensus analyst rating for Ocuphire Pharma?

Ocuphire Pharma currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OCUP will outperform the market and that investors should add to their positions of Ocuphire Pharma.
View the latest ratings for OCUP.

What other companies compete with Ocuphire Pharma?

How do I contact Ocuphire Pharma's investor relations team?

Ocuphire Pharma's physical mailing address is 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD, 20850. The company's listed phone number is (248) 681-9815 and its investor relations email address is [email protected] The official website for Ocuphire Pharma is www.ocuphire.com.